A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia Clinical Trial

Official title:

A First-In-Human, Open-Label, Escalating Multiple-Dose Study to Evaluate the Safety, Toxicity, and Pharmacokinetics of BTX-A51 Alone and in Combination With Azacitidine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04243785
• Other study ID #: BTX-A51-001
• Status: Recruiting
• Phase: Phase 1
• Start date: January 6, 2020
• Est. completion date: March 2027

Study information

• Verified date: February 2024
• Source: Edgewood Oncology Inc.
• Contact: Zung Thai, MD
• Phone: 415-225-9338
• Email: zung[@]edgewoodonc.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, dose escalation study to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-A51 capsules in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).

The study will be done in three parts. Part 1a (Monotherapy Dose Escalation) of this study is designed to determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of orally administered BTX-A51 in up to 35 participants who are evaluable for toxicity. Once the MTD is determined, it is planned that an additional 15 participants will be enrolled in Part 1b (Monotherapy Cohort Expansion) of this study for additional experience with safety and efficacy, and to determine the recommended Phase 2 dose (RP2D) which may or may not be different from the MTD. After determination of MTD and RP2D from Part 1a, Part 1c (Azacitidine Combination Dose Escalation) will enroll up to 30 participants.

Continued treatment will be available under this study protocol for up to eight 28-day cycles (Continued Treatment Phase) if the Investigator judges the benefit outweighs the risk.

Once BTX-A51 treatment has completed, participants will be contacted by telephone every 3 months for up to 2 years after their last treatment for survival status and anticancer therapy (Overall Survival Follow-up).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: March 2027
• Est. primary completion date: March 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Demonstration of understanding and voluntarily signing of an informed consent form

• Age = 18 years

• Diagnosis of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) according to the World Health Organization classification and, with respect to MDS, that is high risk; participants must have refractory or relapsed disease and be ineligible for or have exhausted standard therapeutic options that would otherwise be likely to provide clinical benefit

• Eastern Cooperative Oncology Group performance status = 2 and life expectancy of = 6 weeks

• Adequate organ function (Grade 1 serum creatinine; Grade 1 total bilirubin; aspartate aminotransferase and/or alanine transaminase = 2 × ULN)

• Females of childbearing age must not be pregnant at time of Screening/beginning of treatment and agree to either abstain from sexual intercourse or use highly effective methods of contraception (for up to 3 months after last dose of study drug)

• Males sexually active with a woman of childbearing age must agree to use barrier method of birth control during and after the study (up to 3 months after last dose of study drug)

Exclusion Criteria:

• Diagnosis of acute promyelocytic leukemia

• White blood cell count > 20 x 10^9/L

• Receipt of cancer chemotherapy (other than hydroxyurea) within 2 weeks prior to the start of study drug

• In participants who have undergone autologous or allogeneic stem cell transplantation:

transplantation within the 3 months prior to Screening; active graft-versus-host disease requiring anything other than topical corticosteroids and budesonide; treatment with systemic immunosuppressive medications including high-dose steroids (= 20 mg prednisolone or equivalent per day), or calcineurin inhibitors (e.g., cyclosporine, tacrolimus) for at least 1 week prior to Screening, and sirolimus, mycophenylate mofetil, azathioprine, or ruxolitinib for at least 2 weeks prior to Screening

• Immediate life-threatening severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation

• Persistent toxicities from prior treatment of Grade 2 or higher

• Active uncontrolled systemic fungal, bacterial, mycobacterial, or viral infection

• Clinically significant cardiac disease

• Known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally

• Any other concurrent medical condition or disease that is likely to interfere with study procedures or results, or that, in the opinion of the Investigator, would constitute a hazard for participating in this study

• If female, pregnant or breastfeeding

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Myelodysplastic Syndrome
• Myelodysplastic Syndromes
• Preleukemia
• Syndrome

Intervention

Drug:
• BTX-A51
Orally administered capsules available in strengths of 0.5 mg, 1.0 mg, 2.0 mg and 7 mg.
• Azacitidine
Azacitidine will be administered IV or SC 75 mg/m2 QD on Days 1-7 of each 28-day cycle.

Locations

Country	Name	City	State
United States	City of Hope National Medical Center	Duarte	California
United States	The University of Texas MD Anderson Cancer Center	Houston	Texas
United States	Memorial Sloan-Kettering Cancer Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Edgewood Oncology Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of dose-limiting toxicities (DLTs)	A DLT is defined as a severe or clinically significant adverse event (AE) or abnormal laboratory value (Grade 3 or greater, unless otherwise specified) starting with the first dose on Cycle 1 Day 1, unless it is clearly related to disease progression, intercurrent illness, preexisting condition, or concomitant medications. DLTs are based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.	Up to a total of eight 28-day cycles (approximately 224 days)
Primary	Number of participants with non-serious AEs and serious AEs (SAEs)	The severity/intensity of AEs will be graded based upon the participant's symptoms according to the NCI CTCAE Version 5.0	Up to a total of eight 28-day cycles (approximately 224 days)
Primary	Number of participants with laboratory abnormalities and/or AEs	Number of participants with potentially clinically significant laboratory values; toxicity will be graded and reported according to the NCI CTCAE Version 5.0	Up to a total of eight 28-day cycles (approximately 224 days)
Primary	Number of participants with 12-lead electrocardiogram (ECG) abnormalities and/or AEs	Number of participants with potentially clinically significant 12-lead ECG findings; toxicity will be graded and reported according to the NCI CTCAE Version 5.0	Up to a total of eight 28-day cycles (approximately 224 days)
Primary	Number of participants with echocardiogram (ECHO) abnormalities and/or AEs	Number of participants with potentially clinically significant ECHO abnormalities and/or AEs, such as elevated or abnormal left ventricular ejection fraction (LVEF) or abnormal Global Longitudinal Strain (GLS)	Up to a total of eight 28-day cycles (approximately 224 days)
Primary	Number of participants with vital sign abnormalities and/or AEs	Number of participants with potentially clinically significant vital sign values; toxicity will be graded and reported according to the NCI CTCAE Version 5.0	Up to a total of eight 28-day cycles (approximately 224 days)
Primary	Number of participants with physical examination abnormalities and/or AEs	Number of participants with potentially clinically significant physical examination findings; toxicity will be graded and reported according to the NCI CTCAE Version 5.0	Up to a total of eight 28-day cycles (approximately 224 days)
Primary	Maximum tolerated dose (MTD)	The DLTs are to be evaluated for determination of the MTD. The MTD will be the dose for which the isotonic estimate of the toxicity rate is closest to the target toxicity rate of 0.3. If there are ties, the higher dose level when the isotonic estimate is lower than the target toxicity rate will be identified and the lower dose level selected when the isotonic estimate is greater than or equal to the target toxicity rate.	Up to 28 days (one cycle) for each dosing cohort in Phase 1a
Primary	Recommended Phase 2 dose (RP2D)	The DLTs are to be evaluated based on cumulative safety/PK data in participants treated in Phase 1b for determination of the RP2D (which may or may not differ from the MTD)	Up to 28 days (one cycle) for each dosing cohort in Phase 1b
Secondary	Complete remission (CR) for participants with acute myeloid leukemia (AML)	CR is defined as free of all symptoms related to leukemia and with an absolute neutrophil count (ANC) = 1.0 × 10^9/L (1000/µL), platelet count = 100 × 10^9/L (100,000/µL), and normal bone marrow (BM) with < 5 percent blasts; absence of circulating blasts and blasts with Auer rods	Up to a total of eight 28-day cycles (approximately 224 days)
Secondary	Complete remission with incomplete blood count recovery (CRi) for participants with AML	CRi is defined as all CR criteria except for residual neutropenia (ANC < 1.0 × 10^9/L [1000/µL]) or thrombocytopenia (platelet count < 100 × 10^9/L [100,000/µL])	Up to a total of eight 28-day cycles (approximately 224 days)
Secondary	Morphologic leukemia-free state (MLFS) for participants with AML	MLFS is defined as BM blasts < 5 percent; absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required. Marrow should not barely be "aplastic;" at least 200 cells should be enumerated or cellularity should be at least 10 percent.	Up to a total of eight 28-day cycles (approximately 224 days)
Secondary	Partial remission (PR) for participants with AML	PR is defined as all hematologic criteria of CR; decrease of BM blast percentage to 5 - 25 percent; and decrease of pretreatment BM blast percentage by at least 50 percent	Up to a total of eight 28-day cycles (approximately 224 days)
Secondary	Complete remission (CR) for participants with high-risk myelodysplastic syndrome (MDS)	CR is defined as free of all symptoms related to leukemia and with an ANC = 1.0 × 10^9/L, platelet count = 100 × 10^9/L, BM = 5 percent myeloblasts, with normal maturation of all cell lines, hemoglobin = 11 g/dL, and no blasts in peripheral blood (PB)	Up to a total of eight 28-day cycles (approximately 224 days)
Secondary	Partial remission (PR) for participants with high-risk MDS	PR is defined as all CR criteria with = 50 percent decrease in BM blasts over pre-treatment (but still > 5 percent)	Up to a total of eight 28-day cycles (approximately 224 days)
Secondary	Hematologic improvement (HI) for participants with high-risk MDS	The International Working Group criteria for HI defining specific responses of cytopenias in the three hematopoietic lineages: erythroid (HI-E), platelet (HI-P), and neutrophil (HI-N)	Up to a total of eight 28-day cycles (approximately 224 days)
Secondary	Overall survival and event-free survival in participants with AML or high-risk MDS	Follow-up will occur by telephone contact once every 3 months for assessment of survival status and bone marrow transplant (BMT) conditioning or other new antineoplastic therapies since discontinuation of study drug; the cause of death will be documented. Disease assessment will be collected for participants who discontinue study medication due to any reason other than progression or death. If a participant has not progressed or died, progression-free survival is censored at the date of last follow up. The distribution of time-to-event endpoints will be estimated using the method of Kaplan and Meier.	Up to 2 years after participant's last dose of BTX-A51 or upon death, whichever occurs first
Secondary	PK parameter: Maximum observed plasma concentration (Cmax)	Maximum observed plasma drug concentration after the first dose	During Cycle 1 for each dosing cohort in Phase 1a on Days 1, 3, and 5 (pre-dose and approximately 1, 2, 3, 5, 8, and 12 hours post-dose); Days 2, 4, 6, 7, 8; and Day 15 (pre-dose and approximately 1, 2, 3, 5, 8, and 12 hours post-dose)
Secondary	PK parameter: Time of maximum plasma concentration (Tmax)	Time to reach Cmax	During Cycle 1 for each dosing cohort in Phase 1a on Days 1, 3, and 5 (pre-dose and approximately 1, 2, 3, 5, 8, and 12 hours post-dose); Days 2, 4, 6, 7, 8; and Day 15 (pre-dose and approximately 1, 2, 3, 5, 8, and 12 hours post-dose)
Secondary	PK parameter: Plasma CmaxD5	Maximum observed plasma drug concentration after the dose on Day 5	During Cycle 1 for each dosing cohort in Phase 1a on Days 1, 3, and 5 (pre-dose and approximately 1, 2, 3, 5, 8, and 12 hours post-dose); Days 2, 4, 6, 7, 8; and Day 15 (pre-dose and approximately 1, 2, 3, 5, 8, and 12 hours post-dose)
Secondary	PK parameter: Plasma TmaxD5	Time to reach CmaxD5	During Cycle 1 for each dosing cohort in Phase 1a on Days 1, 3, and 5 (pre-dose and approximately 1, 2, 3, 5, 8, and 12 hours post-dose); Days 2, 4, 6, 7, 8; and Day 15 (pre-dose and approximately 1, 2, 3, 5, 8, and 12 hours post-dose)
Secondary	PK parameter: C0	Pre-dose concentrations in PK blood samples on dosing days	During Cycle 1 for each dosing cohort in Phase 1a on Days 1, 3, and 5 (pre-dose and approximately 1, 2, 3, 5, 8, and 12 hours post-dose); Days 2, 4, 6, 7, 8; and Day 15 (pre-dose and approximately 1, 2, 3, 5, 8, and 12 hours post-dose)
Secondary	PK parameter: AUC0-24	Area under the curve from time 0 to 24 hours after the first dose	During Cycle 1 for each dosing cohort in Phase 1a on Days 1, 3, and 5 (pre-dose and approximately 1, 2, 3, 5, 8, and 12 hours post-dose); Days 2, 4, 6, 7, 8; and Day 15 (pre-dose and approximately 1, 2, 3, 5, 8, and 12 hours post-dose)
Secondary	PK parameter: AUC0-24D5	AUC from time 0 to 24 hours after the dose on Day 5	During Cycle 1 for each dosing cohort in Phase 1a on Days 1, 3, and 5 (pre-dose and approximately 1, 2, 3, 5, 8, and 12 hours post-dose); Days 2, 4, 6, 7, 8; and Day 15 (pre-dose and approximately 1, 2, 3, 5, 8, and 12 hours post-dose)
Secondary	PK parameter: Terminal elimination rate constant (Kel)	Calculated by linear least-squares regression analysis from a semi-log plot of the plasma concentration versus time curve after the Day 5 dose	During Cycle 1 for each dosing cohort in Phase 1a on Days 1, 3, and 5 (pre-dose and approximately 1, 2, 3, 5, 8, and 12 hours post-dose); Days 2, 4, 6, 7, 8; and Day 15 (pre-dose and approximately 1, 2, 3, 5, 8, and 12 hours post-dose)
Secondary	PK parameter: Terminal elimination phase half-life (t1/2)	Estimated after the Day 5 dose, calculated as 0.693/Kel	During Cycle 1 for each dosing cohort in Phase 1a on Days 1, 3, and 5 (pre-dose and approximately 1, 2, 3, 5, 8, and 12 hours post-dose); Days 2, 4, 6, 7, 8; and Day 15 (pre-dose and approximately 1, 2, 3, 5, 8, and 12 hours post-dose)